Search

Art of Drug Choice Header Bar

Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Editorially Independent content supported with advertising by Novartis and Alcon.

A Breakthrough After Monthly Wet AMD Therapy

Nikolas J.S. London, MD

Show Description +

Nikolas J.S. London, MD, reviews the case of a patient with wet AMD who presented with persistent intraretinal fluid and symptomatic, large pigment epithelial detachment. The patient underwent monthly therapy with various anti-VEGF agents, none of which consistently controlled the disease. In December 2019 the patient underwent therapy with brolucizumab (Beovu, Novartis) and has since received seven injections of the drug. Listen to a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.

Posted: 10/22/2020

Keywords:

Wet AMD

Up Next

Navigating Treatment Burden in Wet AMD

Navigating Treatment Burden in Wet AMD

Christina Weng, MD, MBA

Outside-the-Box Therapy for Wet AMD

Outside-the-Box Therapy for Wet AMD

Christopher G. Fuller, MD

The Value of Treatment Options in Wet AMD

The Value of Treatment Options in Wet AMD

Justus G. Garweg, MD

Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Seenu M. Hariprasad, MD

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Peter Kertes, MD, FRCS(C)

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Arshad M. Khanani, MD, MA

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Arshad M. Khanani, MD, MA

Switching Agents Multiple Times in a Long-term Wet AMD Patient

Switching Agents Multiple Times in a Long-term Wet AMD Patient

Lejla Vajzovic, MD

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Joseph M. Coney, MD

Increasing Treatment Intervals in Wet AMD

Increasing Treatment Intervals in Wet AMD

Arshad M. Khanani, MD

Back to All Videos

A Breakthrough After Monthly Wet AMD Therapy

Nikolas J.S. London, MD

Nikolas J.S. London, MD, reviews the case of a patient with wet AMD who presented with persistent intraretinal fluid and symptomatic, large pigment epithelial detachment. The patient underwent monthly therapy with various anti-VEGF agents, none of which consistently controlled the disease. In December 2019 the patient underwent therapy with brolucizumab (Beovu, Novartis) and has since received seven injections of the drug. Listen to a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.

Posted: 10/22/2020

Keywords:

Wet AMD

Please log in to leave a comment.

Listen as a Podcast

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.